Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Authors: Joyner et al. 

Link to paper:             

Journal/ Pre-Print: MedRxiv 

Tags; Bioinformatics, Clinical/ Diagnostics, Therapeutics 

Research Highlights

  1. Meta-analysis including 12 studies describing treatment with convalescent plasma (CP) to reduce mortality in severe COVID-19 patients found reduced mortality (13%) compared to controls (25%; odds ratio 0.43, P < 0.001). 

  1. Difference between median cohort age, proportion receiving mechanical ventilation, duration of study follow up were not found to affect the aggregate OR (coefficients P > 0.22). 


Joyner et al. carried out a meta-analysis of 12 studies involving the treatment of severe COVID-19 patients with CP. 3 of these studies were randomised clinical trials, 5 were matched controls, and 4 case series, which amounts to a total of 804 COVID-19 patient outcomes. The aggregate of these studies found that CP treatment reduced mortality to 13% compared to 25% for non-transfused (adds ratio 0.43, P <0.001). The authors suggest that since CP was administered later in disease progression in these studies, their analysis may underestimate mortality reduction achievable in this approach. 

Impact for SARS-CoV2/COVID19 research efforts 

Treatment of SARS-CoV2/COVID19 positive individuals - Study aims to bring statistical clarity to the use of CP to reduce mortality in severe COVID-19 

Study Type 

  • In silico study / bioinformatics study  

Strengths and limitations of the paper 

Novelty: Provides statistically relevant information on the reduction of mortality rates in COVID-19 after treatment with CP in the absence of a large scale Randomised Controlled Trial 

Standing in the field: Uses existing papers/studies and provides statistics for the biologically sound rationale of the use of CP in COVID-19. 

Appropriate statistics: Yes, statistics were appropriate and accurate. 

Viral model used: N/A         

Translatability: Provides a basis for further larger-scale RCTs to be carried out investigating the potential of CP to treat COVID-19 patients. 

Main limitations: 

  • Lack of background describing the different studies, e.g. the dose of CP used, timing of CP administration. 

  • Comparison of studies is only based on mortality; time between diagnosis and CP administration, and duration of follow-up after transfusion could have been compared.